Statins in the treatment of acute ischemic stroke

Fabrizio Montecucco, Alessandra Quercioli, Marisol Mirabelli-Badenier, Giorgio Luciano Viviani, François Mach

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are drugs active in the blockade of cholesterol synthesis and thus lowering cholesterol serum levels. Since their discovery, experimental evidence showed that statins strongly reduced atherogenesis and the risk of acute ischemic complications, such as acute myocardial infarction and stroke. More recently, direct anti-atherosclerotic effects of statins (independently of lipid profile improvement) have been also shown, suggesting new potential applications for these drugs in both primary and secondary prevention of acute cardiovascular events. Despite some controversies exist, the use of statins has been shown to improve both incidence and survival in acute ischemic stroke. The molecular mechanisms underlying statin-mediated clinical benefits were recently identified in the reduction of carotid plaque vulnerability and the increase of neuroprotection. In the present review, we will update evidence on the promising results with statins to improve ischemic stroke outcomes.

Original languageEnglish
Pages (from-to)68-76
Number of pages9
JournalCurrent Pharmaceutical Biotechnology
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke
Therapeutics
Cholesterol
Primary Prevention
Secondary Prevention
Pharmaceutical Preparations
Atherosclerosis
Oxidoreductases
Myocardial Infarction
Lipids
Incidence
Serum

Keywords

  • Atherosclerosis
  • Inflammation
  • Neuroprotection
  • Statin
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

Montecucco, F., Quercioli, A., Mirabelli-Badenier, M., Viviani, G. L., & Mach, F. (2012). Statins in the treatment of acute ischemic stroke. Current Pharmaceutical Biotechnology, 13(1), 68-76. https://doi.org/10.2174/138920112798868737

Statins in the treatment of acute ischemic stroke. / Montecucco, Fabrizio; Quercioli, Alessandra; Mirabelli-Badenier, Marisol; Viviani, Giorgio Luciano; Mach, François.

In: Current Pharmaceutical Biotechnology, Vol. 13, No. 1, 01.2012, p. 68-76.

Research output: Contribution to journalArticle

Montecucco, F, Quercioli, A, Mirabelli-Badenier, M, Viviani, GL & Mach, F 2012, 'Statins in the treatment of acute ischemic stroke', Current Pharmaceutical Biotechnology, vol. 13, no. 1, pp. 68-76. https://doi.org/10.2174/138920112798868737
Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. Current Pharmaceutical Biotechnology. 2012 Jan;13(1):68-76. https://doi.org/10.2174/138920112798868737
Montecucco, Fabrizio ; Quercioli, Alessandra ; Mirabelli-Badenier, Marisol ; Viviani, Giorgio Luciano ; Mach, François. / Statins in the treatment of acute ischemic stroke. In: Current Pharmaceutical Biotechnology. 2012 ; Vol. 13, No. 1. pp. 68-76.
@article{9d8e70d9b65343f593c3fa4726992c71,
title = "Statins in the treatment of acute ischemic stroke",
abstract = "3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are drugs active in the blockade of cholesterol synthesis and thus lowering cholesterol serum levels. Since their discovery, experimental evidence showed that statins strongly reduced atherogenesis and the risk of acute ischemic complications, such as acute myocardial infarction and stroke. More recently, direct anti-atherosclerotic effects of statins (independently of lipid profile improvement) have been also shown, suggesting new potential applications for these drugs in both primary and secondary prevention of acute cardiovascular events. Despite some controversies exist, the use of statins has been shown to improve both incidence and survival in acute ischemic stroke. The molecular mechanisms underlying statin-mediated clinical benefits were recently identified in the reduction of carotid plaque vulnerability and the increase of neuroprotection. In the present review, we will update evidence on the promising results with statins to improve ischemic stroke outcomes.",
keywords = "Atherosclerosis, Inflammation, Neuroprotection, Statin, Stroke, Treatment",
author = "Fabrizio Montecucco and Alessandra Quercioli and Marisol Mirabelli-Badenier and Viviani, {Giorgio Luciano} and Fran{\cc}ois Mach",
year = "2012",
month = "1",
doi = "10.2174/138920112798868737",
language = "English",
volume = "13",
pages = "68--76",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Statins in the treatment of acute ischemic stroke

AU - Montecucco, Fabrizio

AU - Quercioli, Alessandra

AU - Mirabelli-Badenier, Marisol

AU - Viviani, Giorgio Luciano

AU - Mach, François

PY - 2012/1

Y1 - 2012/1

N2 - 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are drugs active in the blockade of cholesterol synthesis and thus lowering cholesterol serum levels. Since their discovery, experimental evidence showed that statins strongly reduced atherogenesis and the risk of acute ischemic complications, such as acute myocardial infarction and stroke. More recently, direct anti-atherosclerotic effects of statins (independently of lipid profile improvement) have been also shown, suggesting new potential applications for these drugs in both primary and secondary prevention of acute cardiovascular events. Despite some controversies exist, the use of statins has been shown to improve both incidence and survival in acute ischemic stroke. The molecular mechanisms underlying statin-mediated clinical benefits were recently identified in the reduction of carotid plaque vulnerability and the increase of neuroprotection. In the present review, we will update evidence on the promising results with statins to improve ischemic stroke outcomes.

AB - 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) are drugs active in the blockade of cholesterol synthesis and thus lowering cholesterol serum levels. Since their discovery, experimental evidence showed that statins strongly reduced atherogenesis and the risk of acute ischemic complications, such as acute myocardial infarction and stroke. More recently, direct anti-atherosclerotic effects of statins (independently of lipid profile improvement) have been also shown, suggesting new potential applications for these drugs in both primary and secondary prevention of acute cardiovascular events. Despite some controversies exist, the use of statins has been shown to improve both incidence and survival in acute ischemic stroke. The molecular mechanisms underlying statin-mediated clinical benefits were recently identified in the reduction of carotid plaque vulnerability and the increase of neuroprotection. In the present review, we will update evidence on the promising results with statins to improve ischemic stroke outcomes.

KW - Atherosclerosis

KW - Inflammation

KW - Neuroprotection

KW - Statin

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84855857737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855857737&partnerID=8YFLogxK

U2 - 10.2174/138920112798868737

DO - 10.2174/138920112798868737

M3 - Article

VL - 13

SP - 68

EP - 76

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 1

ER -